ZA200703002B - Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity - Google Patents

Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity

Info

Publication number: ZA200703002B
Authority: ZA; South Africa
Prior art keywords: biphenyl; obesity; preparation; treatment; acid derivatives
Prior art date: 2004-10-15

Application number

ZA200703002A

Other languages

English (en)

Inventor

Smith Roger

Stephen J O'connor

Coish Philip

Lowe Derek

Roger B Clark

Stebbins Jeffrey

Campbell Ann-Marie

Akuche Christiana

Shelekhin Tatiana

Original Assignee

Bayer Pharmaceuticals Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-15

Filing date

2007-04-12

Publication date

2008-08-27

2007-04-12 Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp

2008-08-27 Publication of ZA200703002B publication Critical patent/ZA200703002B/xx

Links

208000008589 Obesity Diseases 0.000 title abstract 2
239000002253 acid Substances 0.000 title abstract 2
-1 biphenyl-4-yl-carbonylamino Chemical group 0.000 title abstract 2
235000020824 obesity Nutrition 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

ZA200703002A 2004-10-15 2007-04-12 Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity ZA200703002B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US61897504P	2004-10-15	2004-10-15

Publications (1)

Publication Number	Publication Date
ZA200703002B true ZA200703002B (en)	2008-08-27

Family

ID=36203612

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200703002A ZA200703002B (en)	2004-10-15	2007-04-12	Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity

Country Status (21)

Country	Link
US (2)	US7759376B2 (xx)
EP (1)	EP1805156B1 (xx)
JP (1)	JP2008516978A (xx)
KR (1)	KR20070063546A (xx)
CN (1)	CN101087769A (xx)
AT (1)	ATE492542T1 (xx)
AU (1)	AU2005295453A1 (xx)
BR (1)	BRPI0516483A (xx)
CA (1)	CA2583784A1 (xx)
CR (1)	CR9034A (xx)
DE (1)	DE602005025517D1 (xx)
EA (1)	EA200700851A1 (xx)
EC (1)	ECSP077397A (xx)
ES (1)	ES2357015T3 (xx)
IL (1)	IL182218A0 (xx)
MA (1)	MA28935B1 (xx)
MX (1)	MX2007004217A (xx)
NO (1)	NO20072461L (xx)
TN (1)	TNSN07111A1 (xx)
WO (1)	WO2006044775A2 (xx)
ZA (1)	ZA200703002B (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ587106A (en)	2004-12-14	2012-03-30	Astrazeneca Ab	Oxadiazole derivatives as dgat inhibitors
KR20080090400A (ko)	2005-11-21	2008-10-08	애나디스 파마슈티칼스, 인코포레이티드	5-아미노-3Ｈ-티아졸로[4,5-ｄ]피리미딘-2-온의 제조 방법
CN101346387A (zh)	2005-12-22	2009-01-14	阿斯利康(瑞典)有限公司	用作DGAT抑制剂的嘧啶并-[4,5-b]-噁嗪
EP2402318A1 (en)	2006-03-31	2012-01-04	Novartis AG	DGAT inhibitors
BRPI0712796A2 (pt)	2006-05-30	2012-10-02	Astrazeneca Ab	composto, métodos para produzir uma inibição da atividade de dgat1 em um animal de sangue quente, para tratar a diabete melito e/ou a obesidade em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para um composto
BRPI0712802A2 (pt)	2006-05-30	2012-10-23	Astrazeneca Ab	composto, métodos para produzir uma inibição da atividade de dgat1, e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para preparar um composto
KR100811100B1 (ko)	2006-09-27	2008-03-06	한국생명공학연구원	벤즈아졸 유도체를 유효성분으로 함유하는 대사성 질환예방 및 치료용 약학적 조성물
KR100795462B1 (ko)	2006-09-27	2008-01-16	한국생명공학연구원	인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물
AR063311A1 (es) *	2006-10-18	2009-01-21	Novartis Ag	Compuestos organicos
WO2008073865A2 (en) *	2006-12-11	2008-06-19	Novartis Ag	Method of preventing or treating myocardial ischemia
WO2008148840A1 (en)	2007-06-08	2008-12-11	Janssen Pharmaceutica N.V.	Piperidine/piperazine derivatives
JO2972B1 (en)	2007-06-08	2016-03-15	جانسين فارماسوتيكا ان. في	Piperidine / piperazine derivatives
CA2687918C (en) *	2007-06-08	2016-11-08	Janssen Pharmaceutica N.V.	Piperidine/piperazine derivatives
CA2687754C (en)	2007-06-08	2015-12-08	Janssen Pharmaceutica N.V.	Piperidine, piperazine derivatives for use as dgat inhibitors
AR066169A1 (es)	2007-09-28	2009-07-29	Novartis Ag	Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
TW200932235A (en)	2007-12-20	2009-08-01	Astrazeneca Ab	Carbamoyl compounds as DGAT1 inhibitors
HUE035963T2 (en)	2008-05-05	2018-05-28	Sanofi Sa	Acylamino-substituted condensed cyclopentanecarboxylic acid derivatives and their use as medicaments
PE20100083A1 (es)	2008-06-05	2010-02-17	Janssen Pharmaceutica Nv	Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
WO2010072712A1 (en) *	2008-12-23	2010-07-01	Novartis Ag	Biaryl benzylamine derivatives
CA2749700A1 (en) *	2009-01-23	2010-07-29	Msd K.K.	Benzodiazepin-2-on derivatives
WO2010108051A2 (en)	2009-03-20	2010-09-23	Ligand Pharmaceuticals	Inhibitors of diacylglycerol o-acyltransferase 1(dgat-1) and uses thereof
US8268820B2 (en)	2009-03-26	2012-09-18	Hoffmann-La Roche Inc.	2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds
WO2010111665A1 (en)	2009-03-27	2010-09-30	Bristol-Myers Squibb Company	Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
RU2011152517A (ru)	2009-06-19	2013-07-27	Астразенека Аб	Пиразинкарбоксамиды в качестве ингибиторов dgat1
AR079022A1 (es)	2009-11-02	2011-12-21	Sanofi Aventis	Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
RU2012149806A (ru)	2009-11-05	2014-05-27	Пирамал Энтерпрайзис Лимитед	Карбоксиоксазольные или тиазольные соединения в качестве ингибиторов dgat-1, пригодные для лечения ожирения
MX341841B (es)	2009-12-16	2016-09-05	Pola Chem Ind Inc	Agente de prevencion o mejoramiento para la pigmentacion.
JP2013523746A (ja)	2010-03-30	2013-06-17	ノバルティスアーゲー	Ｄｇａｔ１阻害剤の使用
WO2012150784A2 (ko)	2011-05-03	2012-11-08	한국생명공학연구원	신규한 인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
WO2013055910A1 (en)	2011-10-12	2013-04-18	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014039412A1 (en)	2012-09-05	2014-03-13	Bristol-Myers Squibb Company	Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
EP2892896B1 (en)	2012-09-05	2016-06-29	Bristol-Myers Squibb Company	Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
WO2014074668A1 (en)	2012-11-08	2014-05-15	Arena Pharmaceuticals, Inc.	Modulators of gpr119 and the treatment of disorders related thereto
RU2729998C9 (ru) *	2014-08-01	2020-10-20	Байер Фарма Акциенгезельшафт	Способ получения (4s)-4-(4-циано-2-метоксифенил)-5-этокси-2,8-диметил-1,4-дигидро-1,6-нафтиридин-3-карбоксамида и его очистки для применения в качестве фармацевтического активного ингредиента
CN105646510A (zh) *	2014-12-02	2016-06-08	重庆宁牧生态农业有限公司	一种用作抗肥胖剂的化合物
CN111936137B (zh)	2018-03-16	2023-09-08	安济药业公司	用于治疗严重便秘的组合物和方法
US20220304984A1 (en) *	2019-06-12	2022-09-29	Vanderbilt University	Amino acid transport inhibitors and the uses thereof
CN112336718A (zh) *	2020-10-19	2021-02-09	济南大学	一种苯并咪唑衍生物作为α-葡萄糖苷酶抑制剂及其应用
WO2023085931A1 (en)	2021-11-11	2023-05-19	Koninklijke Nederlandse Akademie Van Wetenschappen	Hepatic organoids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4164645B2 (ja) *	2002-08-09	2008-10-15	株式会社大塚製薬工場	Ｄｇａｔ阻害剤
KR100772297B1 (ko) *	2002-11-22	2007-11-02	니뽄 다바코 산교 가부시키가이샤	융합 비시클릭 질소-함유 헤테로사이클
AR044152A1 (es) *	2003-05-09	2005-08-24	Bayer Corp	Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad

2005
- 2005-10-14 CA CA002583784A patent/CA2583784A1/en not_active Abandoned
- 2005-10-14 US US11/665,317 patent/US7759376B2/en not_active Expired - Fee Related
- 2005-10-14 BR BRPI0516483-4A patent/BRPI0516483A/pt not_active IP Right Cessation
- 2005-10-14 KR KR1020077008522A patent/KR20070063546A/ko not_active Withdrawn
- 2005-10-14 EP EP05812611A patent/EP1805156B1/en not_active Not-in-force
- 2005-10-14 JP JP2007536988A patent/JP2008516978A/ja active Pending
- 2005-10-14 AT AT05812611T patent/ATE492542T1/de not_active IP Right Cessation
- 2005-10-14 WO PCT/US2005/037215 patent/WO2006044775A2/en active Application Filing
- 2005-10-14 ES ES05812611T patent/ES2357015T3/es active Active
- 2005-10-14 MX MX2007004217A patent/MX2007004217A/es not_active Application Discontinuation
- 2005-10-14 DE DE602005025517T patent/DE602005025517D1/de active Active
- 2005-10-14 CN CNA2005800433280A patent/CN101087769A/zh active Pending
- 2005-10-14 EA EA200700851A patent/EA200700851A1/ru unknown
- 2005-10-14 AU AU2005295453A patent/AU2005295453A1/en not_active Abandoned
2007
- 2007-03-27 IL IL182218A patent/IL182218A0/en unknown
- 2007-03-28 TN TNP2007000111A patent/TNSN07111A1/en unknown
- 2007-03-30 CR CR9034A patent/CR9034A/es not_active Application Discontinuation
- 2007-04-12 ZA ZA200703002A patent/ZA200703002B/xx unknown
- 2007-04-13 EC EC2007007397A patent/ECSP077397A/es unknown
- 2007-04-17 MA MA29831A patent/MA28935B1/fr unknown
- 2007-05-14 NO NO20072461A patent/NO20072461L/no not_active Application Discontinuation
2010
- 2010-07-14 US US12/836,035 patent/US20110118302A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2005295453A1 (en)	2006-04-27
US20070265298A1 (en)	2007-11-15
CR9034A (es)	2008-11-18
DE602005025517D1 (de)	2011-02-03
EP1805156A4 (en)	2009-06-10
US7759376B2 (en)	2010-07-20
NO20072461L (no)	2007-07-03
BRPI0516483A (pt)	2008-09-02
MA28935B1 (fr)	2007-10-01
CA2583784A1 (en)	2006-04-27
WO2006044775A2 (en)	2006-04-27
ATE492542T1 (de)	2011-01-15
CN101087769A (zh)	2007-12-12
MX2007004217A (es)	2007-06-11
IL182218A0 (en)	2007-09-20
TNSN07111A1 (en)	2008-06-02
EP1805156B1 (en)	2010-12-22
EA200700851A1 (ru)	2007-12-28
JP2008516978A (ja)	2008-05-22
US20110118302A1 (en)	2011-05-19
WO2006044775A3 (en)	2006-06-15
EP1805156A2 (en)	2007-07-11
ES2357015T3 (es)	2011-04-15
KR20070063546A (ko)	2007-06-19
ECSP077397A (es)	2007-05-30

Publication	Publication Date	Title
TNSN07111A1 (en)	2008-06-02	Preparation and use of biphenyl-4-yl- carbonylamino acid derivatives for the treatment of obesity.
MXPA05012061A (es)	2006-02-22	Preparacion y uso de derivados alquilarilo para el tratamiento de la obesidad.
WO2007016538A3 (en)	2007-10-04	Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
WO2006113919A3 (en)	2006-11-30	Aryl alkyl acid derivatives for and use thereof
NO20081421L (no)	2008-05-23	Midler for hindring og behandling av forstyrrelser som involverer modulering av RYR-reseptorer
MY145077A (en)	2011-12-15	Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2007068894A3 (en)	2007-12-06	Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
EA201690265A3 (ru)	2016-10-31	Фармацевтические композиции, содержащие замещенные ациланилиды
HK1166983A1 (zh)	2012-11-16	包含用於治療疾病或紊亂的化合物的固體形式，其組合物，及其用途
TW200724543A (en)	2007-07-01	Heterocyclic compounds and their uses as therapeutic agents
NO20064325L (no)	2006-11-22	Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
CR9347A (es)	2007-12-17	Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
MX2007005590A (es)	2007-05-24	Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas.
MX2009003981A (es)	2009-04-27	Agentes moduladores del receptor de calcio.
WO2007016338A3 (en)	2007-12-21	Use of chk2 kinase inhibitors for cancer treatment
MX2010003269A (es)	2010-08-02	Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
MXPA05004621A (es)	2005-06-08	Derivados de anilinopirazol utiles en el tratamiento de la diabetes.
UA90698C2 (xx)	2010-05-25	Триазолзаміщені амінобензофенонові сполуки$триазолзамещеные аминобензофеноновые соединения
TW200628473A (en)	2006-08-16	Novel heterocycles
WO2005112923A3 (en)	2006-09-14	5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
WO2009151495A3 (en)	2010-08-26	Oxazole compounds, compositions and methods of use
TW200603791A (en)	2006-02-01	Compounds and compositions as cathepsin S inhibitors
UA86051C2 (xx)	2009-03-25	Заміщені хіноліни[замещенные хинолины
TW200628453A (en)	2006-08-16	Triazole substituted aminobenzophenone compounds
UA87851C2 (ru)	2009-08-25	Производные пирролотриазина, применимые для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом